Cargando…

Stereotactic Body Radiotherapy for Primary Prostate Cancer

Prostate cancer is the most common non-cutaneous cancer in males. There are a number of options for patients with localized early stage disease, including active surveillance for low-risk disease, surgery, brachytherapy, and external beam radiotherapy. Increasingly, external beam radiotherapy, in th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kothari, Gargi, Loblaw, Andrew, Tree, Alison C., van As, Nicholas J., Moghanaki, Drew, Lo, Simon S., Ost, Piet, Siva, Shankar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069023/ https://www.ncbi.nlm.nih.gov/pubmed/30064301 http://dx.doi.org/10.1177/1533033818789633

Ejemplares similares

Stereotactic ablative body radiotherapy in patients with prostate cancer
por: Loblaw, Andrew, et al.
Publicado: (2018)

Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer
por: Patel, Priyanka H., et al.
Publicado: (2019)

Stereotactic Body Radiotherapy: Hitting Harder, Faster, and Smarter in High-Risk Prostate Cancer
por: Correa, Rohann J. M., et al.
Publicado: (2022)

Prostate stereotactic body radiotherapy with simultaneous integrated boost: which is the best planning method?
por: Tree, Alison, et al.
Publicado: (2013)

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence
por: Decaestecker, Karel, et al.
Publicado: (2014)

Clinical evaluation of an endorectal immobilization system for use in prostate hypofractionated Stereotactic Ablative Body Radiotherapy (SABR)
por: Nicolae, Alexandru, et al.
Publicado: (2015)

Dosimetric Implications of Computerised Tomography-Only versus Magnetic Resonance-Fusion Contouring in Stereotactic Body Radiotherapy for Prostate Cancer
por: Henderson, Daniel R., et al.
Publicado: (2018)

Complications from Stereotactic Body Radiotherapy for Lung Cancer
por: Kang, Kylie H., et al.
Publicado: (2015)

Imaging Biomarkers in Prostate Stereotactic Body Radiotherapy: A Review and Clinical Trial Protocol
por: Liu, Wei, et al.
Publicado: (2022)

Stereotactic Body Radiotherapy for Oligometastatic Disease in Non-small Cell Lung Cancer
por: Wujanto, Caryn, et al.
Publicado: (2019)

Stereotactic Body Radiotherapy for Prostate Cancer
por: Parikh, Neil R., et al.
Publicado: (2020)

Prognostic impact of biologically equivalent dose in stereotactic body radiotherapy for renal cancer
por: Tran, Kevin T., et al.
Publicado: (2023)

Dose matters for stereotactic body radiotherapy for early stage non-small cell lung cancer
por: Okoye, Christian C., et al.
Publicado: (2020)

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
por: Brand, Douglas H, et al.
Publicado: (2019)

Editorial: Stereotactic body radiotherapy for prostate cancer
por: Kishan, Amar U., et al.
Publicado: (2022)

Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer
por: Kishan, Amar U., et al.
Publicado: (2019)

Technical know‐how in stereotactic ablative radiotherapy (SABR)
por: Lo, Simon S., et al.
Publicado: (2016)

Stereotactic radiotherapy with focal boost for intermediate and high-risk prostate cancer: Initial results of the SPARC trial
por: Nicholls, Luke, et al.
Publicado: (2020)

NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy
por: Hardcastle, Nicholas, et al.
Publicado: (2019)

Curing Operable Stage I Non-Small Cell Lung Cancer With Stereotactic Ablative Body Radiotherapy: The Force Awakens
por: Siva, Shankar, et al.
Publicado: (2016)

Stereotactic body radiotherapy for organ-confined prostate cancer
por: Katz, Alan J, et al.
Publicado: (2010)

Prostate stereotactic body radiotherapy: quantifying intra-fraction motion and calculating margins using the new BIR geometric uncertainties in daily online IGRT recommendations
por: McNeice, Joseph M, et al.
Publicado: (2023)

The Judicious Use of Stereotactic Ablative Radiotherapy in the Primary Management of Localized Renal Cell Carcinoma
por: Barbour, Andrew B., et al.
Publicado: (2023)

A phase III randomized-controlled, single-blind trial to improve quality of life with stereotactic body radiotherapy for patients with painful bone metastases (ROBOMET)
por: Mercier, Carole, et al.
Publicado: (2019)

Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer
por: Pepin, Abigail N., et al.
Publicado: (2022)

Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma?
por: Rühle, Alexander, et al.
Publicado: (2019)

Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer
por: Hardcastle, Nicholas, et al.
Publicado: (2021)

Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours
por: Goldsmith, Christy, et al.
Publicado: (2012)

Evolution of Hypofractionated Accelerated Radiotherapy for Prostate Cancer – The Sunnybrook Experience
por: Musunuru, Hima Bindu, et al.
Publicado: (2014)

Ablative Radiotherapy in Prostate Cancer: Stereotactic Body Radiotherapy and High Dose Rate Brachytherapy
por: Ma, Ting Martin, et al.
Publicado: (2020)

Dose-Escalated Stereotactic Body Radiation Therapy for Prostate Cancer: Quality-of-Life Comparison of Two Prospective Trials
por: Quon, Harvey C., et al.
Publicado: (2016)

Diffusion weighted and dynamic contrast enhanced MRI as an imaging biomarker for stereotactic ablative body radiotherapy (SABR) of primary renal cell carcinoma
por: Reynolds, Hayley M., et al.
Publicado: (2018)

Editorial: Clinical Application of Stereotactic Body Radiotherapy (SBRT): Cranium to Prostate
por: Vargo, John A., et al.
Publicado: (2015)

Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma
por: Kim, Hun Jung, et al.
Publicado: (2016)

Developments in Stereotactic Body Radiotherapy
por: Haridass, Anoop
Publicado: (2018)

A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response
por: De Wolf, Katrien, et al.
Publicado: (2017)

Outcomes of stereotactic body radiotherapy for unresectable primary or recurrent cholangiocarcinoma
por: Jung, Da Hoon, et al.
Publicado: (2014)

Clinical Assessment of Prostate Displacement and Planning Target Volume Margins for Stereotactic Body Radiotherapy of Prostate Cancer
por: Levin-Epstein, Rebecca, et al.
Publicado: (2020)

Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial
por: David, Steven, et al.
Publicado: (2019)

The Role of Hypofractionated Radiotherapy in Prostate Cancer
por: Benjamin, Linus C., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bhgld9uk3sku1jfbetki1fv9jb